Dicerna Pharmaceuticals reported $-40815000 in Net Income for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Net Income Change
Acceleron Pharma XLRN:US $ -63.52M 0.05M
Agenus AGEN:US $ -83.29M 29.61M
Alnylam Pharmaceuticals ALNY:US $ -189.56M 10.73M
Amgen AMGN:US $ 464M 1182M
Arrowhead Research ARWR:US $ -29924000 3.11M
Biogen BIIB:US $ 448.5M 38.3M
Bluebird Bio BLUE:US $ -241.7M 35.89M
Dicerna Pharmaceuticals DRNA:US $ -40.82M 10.85M
Exelixis EXEL:US $ 96.09M 94.49M
Gilead Sciences GILD:US $ 1522M 207M
GlaxoSmithKline GSK:LN 1395M 322M
Immunogen IMGN:US $ -30.74M 3.31M
Intercept Pharmaceuticals ICPT:US $ -11.09M 29.33M
IONIS PHARMACEUT IONS:US $ -80.88M 8.99M
Karyopharm Therapeutics KPTI:US $ -53582000 3.83M
Lexicon Pharmaceuticals LXRX:US $ -18.07M 2.89M
Macrogenics MGNX:US $ -39.94M 11.34M
Merk MRK:US $ 1545M 1634M
Mirati Therapeutics MRTX:US $ -166.43M 30.75M
Pfizer PFE:US $ 5564M 686M
Regeneron Pharmaceuticals REGN:US $ 3098.9M 1983.7M
Ultragenyx Pharmaceutical RARE:US $ -122.43M 13.71M